Apellis (APLS) is down -19.3%, or -$5.81 to $24.24.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Buy Rating for Apellis Pharmaceuticals Driven by Strong Financial Performance and Promising Product Developments
- Positive Outlook for Apellis Pharmaceuticals: Strong Performance and Strategic Positioning Support Buy Rating
- Apellis reports Q3 EPS $1.71, consensus 94c
- Apellis price target raised to $24 from $22 at Mizuho
- Apellis Pharmaceuticals’ Promising Phase 2 Study on Geographic Atrophy Treatment